IE55181B1 - Treatment of minimal brain dysfunction(mbd) - Google Patents
Treatment of minimal brain dysfunction(mbd)Info
- Publication number
- IE55181B1 IE55181B1 IE114782A IE114782A IE55181B1 IE 55181 B1 IE55181 B1 IE 55181B1 IE 114782 A IE114782 A IE 114782A IE 114782 A IE114782 A IE 114782A IE 55181 B1 IE55181 B1 IE 55181B1
- Authority
- IE
- Ireland
- Prior art keywords
- preparation
- composition
- compound
- pharmaceutically acceptable
- addition salt
- Prior art date
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims description 12
- 206010027374 Mental impairment Diseases 0.000 title claims description 11
- 238000011282 treatment Methods 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 229960000761 pemoline Drugs 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QVZLDGQCTHYKHH-UHFFFAOYSA-N 5-methyl-n-(2,4,5-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine Chemical compound N12N=CN=C2N=C(C)C=C1NC1=CC(F)=C(F)C=C1F QVZLDGQCTHYKHH-UHFFFAOYSA-N 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010062119 Sympathomimetic effect Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26371781A | 1981-05-14 | 1981-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE821147L IE821147L (en) | 1982-11-14 |
| IE55181B1 true IE55181B1 (en) | 1990-06-20 |
Family
ID=23002963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE114782A IE55181B1 (en) | 1981-05-14 | 1982-05-13 | Treatment of minimal brain dysfunction(mbd) |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS57203048A (enrdf_load_stackoverflow) |
| AU (1) | AU558410B2 (enrdf_load_stackoverflow) |
| IE (1) | IE55181B1 (enrdf_load_stackoverflow) |
| ZA (1) | ZA823321B (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06206817A (ja) * | 1983-08-16 | 1994-07-26 | Wellcome Found Ltd:The | 医薬組成物 |
| US5177111A (en) * | 1989-12-14 | 1993-01-05 | Hoechst-Roussel Pharmaceuticals Inc. | Alkylamino- and alkylamino alkyl diarylketones and pharmaceutical compositions thereof |
| US5006563A (en) * | 1989-12-14 | 1991-04-09 | Hoechst-Roussel Pharmaceuticals Inc. | Alkylamino- and alkylamino alkyl diarylketones |
-
1982
- 1982-05-13 AU AU83658/82A patent/AU558410B2/en not_active Expired
- 1982-05-13 ZA ZA823321A patent/ZA823321B/xx unknown
- 1982-05-13 IE IE114782A patent/IE55181B1/en not_active IP Right Cessation
- 1982-05-13 JP JP8083782A patent/JPS57203048A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57203048A (en) | 1982-12-13 |
| IE821147L (en) | 1982-11-14 |
| AU8365882A (en) | 1982-11-18 |
| AU558410B2 (en) | 1987-01-29 |
| JPH0343248B2 (enrdf_load_stackoverflow) | 1991-07-01 |
| ZA823321B (en) | 1983-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4435449A (en) | Treatment of minimal brain dysfunction (MBD) | |
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| EP0397831B1 (en) | Treatment of obesity | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| HK1006002B (en) | Treatment of obesity | |
| US4393078A (en) | Bupropion and ethanol | |
| US4425363A (en) | Treatment of tardive dyskinesia in mammals | |
| EP0220696A2 (en) | Use of buspirone for preparing pharmaceutical compositions for alleviation of phobic anxiety | |
| US5990175A (en) | Prevention of migraine | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| JPS61145121A (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| EP0171227B1 (en) | Use of propiophenone compound | |
| US5011841A (en) | Treatment of depression | |
| IE55181B1 (en) | Treatment of minimal brain dysfunction(mbd) | |
| WO1995022324A1 (en) | Treatment of migraine headaches and formulations | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JPH06172187A (ja) | 筋ジストロフィー症治療薬 | |
| JPH09136831A (ja) | 血圧上昇薬 | |
| KR960014873B1 (ko) | 제피론을 함유하는 공황(恐慌)장애 경감용 약학 조성물 | |
| DE3821392A1 (de) | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen) | |
| US5472947A (en) | Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis | |
| JPH03246225A (ja) | メランコリーうつ病の治療法 | |
| JPH06102624B2 (ja) | 非心臓由来の不整脈防止薬 | |
| JPH06279282A (ja) | 鎮痛製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |